OBJECTIVES: To ascertain prevalence of peripheral sensory and motor neuropathy, and to evaluate impairments in relation to function. DESIGN: St. Jude Lifetime Cohort Study, a clinical follow-up study designed to evaluate adverse late effects in adult survivors of childhood cancer. SETTING: A children's research hospital. PARTICIPANTS: Eligibility required treatment for an extracranial solid malignancy between 1962 and 2002, age ≥ 18 years, ≥ 10 years postdiagnosis, and no history of cranial radiation. Survivors (N=531) were included in the evaluation with a median age of 32 years and a median time from diagnosis of 25 years. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: Primary exposure measures were cumulative doses of vinca-alkaloid and platinum-based chemotherapies. Survivors with scores ≥ 1 on the sensory subscale of the Modified Total Neuropathy Score were classified with prevalent sensory impairment. Those with sex-specific z scores of ≤-1.3 for dorsiflexion strength were classified with prevalent motor impairment. Participants completed the 6-minute walk test (endurance), the Timed Up & Go test (mobility), and the Sensory Organization Test (balance). RESULTS: The prevalence of sensory and motor impairment was 20% and 17.5%, respectively. Vinca-alkaloid exposure was associated with an increased risk of motor impairment (adjusted odds ratio [OR]=1.66; 95% confidence interval [CI], 1.04-2.64) without evidence for a dose response. Platinum exposure was associated with increased risk of sensory impairment (adjusted OR=1.62; 95% CI, .97-2.72) without evidence of a dose response. Sensory impairment was associated with poor endurance (OR=1.99; 95% CI, .99-4.0) and mobility (OR=1.65; 95% CI, .96-2.83). CONCLUSIONS: Vincristine and cisplatin exposure may increase risk for long-term motor and sensory impairment, respectively. Survivors with sensory impairment are at increased risk for functional performance limitations.
OBJECTIVES: To ascertain prevalence of peripheral sensory and motor neuropathy, and to evaluate impairments in relation to function. DESIGN: St. Jude Lifetime Cohort Study, a clinical follow-up study designed to evaluate adverse late effects in adult survivors of childhood cancer. SETTING: A children's research hospital. PARTICIPANTS: Eligibility required treatment for an extracranial solid malignancy between 1962 and 2002, age ≥ 18 years, ≥ 10 years postdiagnosis, and no history of cranial radiation. Survivors (N=531) were included in the evaluation with a median age of 32 years and a median time from diagnosis of 25 years. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: Primary exposure measures were cumulative doses of vinca-alkaloid and platinum-based chemotherapies. Survivors with scores ≥ 1 on the sensory subscale of the Modified Total Neuropathy Score were classified with prevalent sensory impairment. Those with sex-specific z scores of ≤-1.3 for dorsiflexion strength were classified with prevalent motor impairment. Participants completed the 6-minute walk test (endurance), the Timed Up & Go test (mobility), and the Sensory Organization Test (balance). RESULTS: The prevalence of sensory and motor impairment was 20% and 17.5%, respectively. Vinca-alkaloid exposure was associated with an increased risk of motor impairment (adjusted odds ratio [OR]=1.66; 95% confidence interval [CI], 1.04-2.64) without evidence for a dose response. Platinum exposure was associated with increased risk of sensory impairment (adjusted OR=1.62; 95% CI, .97-2.72) without evidence of a dose response. Sensory impairment was associated with poor endurance (OR=1.99; 95% CI, .99-4.0) and mobility (OR=1.65; 95% CI, .96-2.83). CONCLUSIONS:Vincristine and cisplatin exposure may increase risk for long-term motor and sensory impairment, respectively. Survivors with sensory impairment are at increased risk for functional performance limitations.
Authors: Sandra S Brotherton; Harriet G Williams; Joyce L Gossard; James R Hussey; Bruce A McClenaghan; Paul Eleazer Journal: J Geriatr Phys Ther Date: 2005 Impact factor: 3.381
Authors: Kirsten K Ness; Melissa M Hudson; Ching-Hon Pui; Daniel M Green; Kevin R Krull; Tseng T Huang; Leslie L Robison; E Brannon Morris Journal: Cancer Date: 2011-07-15 Impact factor: 6.860
Authors: Satu S Lehtinen; Usko E Huuskonen; Arja H Harila-Saari; Uolevi Tolonen; Leena K Vainionpää; B Marjatta Lanning Journal: Cancer Date: 2002-05-01 Impact factor: 6.860
Authors: Smita Bhatia; Saro H Armenian; Gregory T Armstrong; Eline van Dulmen-den Broeder; Michael M Hawkins; Leontien C M Kremer; Claudia E Kuehni; Jørgen H Olsen; Leslie L Robison; Melissa M Hudson Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Ellen M Lavoie Smith; Clare Kuisell; Grace A Kanzawa-Lee; Celia M Bridges; Paola Alberti; Guido Cavaletti; Rima Saad; Susanna Park Journal: Lancet Haematol Date: 2020-05 Impact factor: 18.959
Authors: Lang Li; Tammy Sajdyk; Ellen M L Smith; Chien Wei Chang; Claire Li; Richard H Ho; Raymond Hutchinson; Elizabeth Wells; Jodi L Skiles; Naomi Winick; Paul L Martin; Jamie L Renbarger Journal: Clin Pharmacol Ther Date: 2019-01-21 Impact factor: 6.875
Authors: Tejaswi Kandula; Michelle Anne Farrar; Richard J Cohn; David Mizrahi; Kate Carey; Karen Johnston; Matthew C Kiernan; Arun V Krishnan; Susanna B Park Journal: JAMA Neurol Date: 2018-08-01 Impact factor: 18.302
Authors: Kari L Bjornard; Laura S Gilchrist; Hiroto Inaba; Barthelemy Diouf; Marilyn J Hockenberry; Nina S Kadan-Lottick; Daniel C Bowers; M Eileen Dolan; Nicole J Ullrich; William E Evans; Kirsten K Ness Journal: Lancet Child Adolesc Health Date: 2018-09-01
Authors: Vesile Yildiz Kabak; Patrick Calders; Tulin Duger; Jibril Mohammed; Eric van Breda Journal: Support Care Cancer Date: 2018-09-25 Impact factor: 3.603
Authors: Ellen M Lavoie Smith; Lang Li; ChienWei Chiang; Karin Thomas; Raymond J Hutchinson; Elizabeth M Wells; Richard H Ho; Jodi Skiles; Arindom Chakraborty; Celia M Bridges; Jamie Renbarger Journal: J Peripher Nerv Syst Date: 2015-03 Impact factor: 3.494
Authors: Mark R Kelley; James H Wikel; Chunlu Guo; Karen E Pollok; Barbara J Bailey; Randy Wireman; Melissa L Fishel; Michael R Vasko Journal: J Pharmacol Exp Ther Date: 2016-09-08 Impact factor: 4.030
Authors: Tito R Mendoza; Xin Shelley Wang; Loretta A Williams; Qiuling Shi; Elisabeth G Vichaya; Patrick M Dougherty; Sheeba K Thomas; Emre Yucel; Christel C Bastida; Jeanie F Woodruff; Charles S Cleeland Journal: J Pain Date: 2015-07-22 Impact factor: 5.820